FDA Reviews Amgen Osteoporosis Drug Despite Cardiovascular Safety Signal

Jan 16, 2019 | Cardiovascular, Osteoporosis, Patient Safety

Heart Risk

Natalie Grover of ENDPOINTS News reports that the FDA is reviewing romosozumab despite past cardiovascular safety scare. Grover noted the FDA work during horrendous weather and a federal shutdown points toward an interpretation that “the efficacy of the drug in postmenopausal women had been established.”  And recent ENDPOINTS reported that the drug, co-developed by Amgen and UCB, was approved in Japan. Read Ms. Grover’s article for more interesting details.


Pin It on Pinterest